Maximize the Clinical Potential of Your Antibody-Drug Conjugate at World ADC Asia

The 3^rd World ADC Asia is coming to Japan for the first time, as the only meeting focused on antibody-drug conjugate development, bringing together key opinion leaders from the pioneering companies in Asia and the rest of the world including Seattle Genetics, Daiichi Sankyo and Sumitomo Dainippon Pharma Co.

Across 3 days, with 100+ ADC experts, this comprehensive antibody-drug conjugate conference will enable you to propel your ADC pipeline into clinical development. Some of the highlights from the 2020 meeting include exploring targets beyond HER-2; confidently meeting Chinese NMPA regulatory requirements to successfully translate into the clinic and effectively scaling up your manufacturing processes for clinical development. World ADC Asia not only delves into general antibody-drug conjugate challenges, it also focuses on challenges and opportunities specific to development within Asia.

Use this opportunity to network with potential collaborators, foster new connections and further cement existing partnerships.